From the *Division of Allergy, Department of Pediatrics, †Department of Multidisciplinary Laboratory, and ‡Department of Histology and Embryology, Dokuz Eylul University Hospital, Izmir, Turkey.
J Investig Med. 2014 Jan;62(1):56-61. doi: 10.2310/JIM.0000000000000012.
Suplatast tosilate is a medication that inhibits TH2-type cytokines. We aimed to investigate the effects of suplatast tosilate treatment and prophylaxis on lung histopathology and cytokine levels in a mouse model of chronic asthma.
Forty-two BALB/c mice were divided into 6 groups: group I (control), group II (vehicle control), group III (dexamethasone), group IV (prophylaxis with suplatast tosilate), group V (treatment with suplatast tosilate), and group VI (prophylaxis and treatment with suplatast tosilate). All of the groups, except for the control and vehicle control groups, were sensitized and challenged with ovalbumin. The mice in the study groups, except those in the group receiving suplatast tosilate for prophylaxis only, were treated with study drugs. After the mice were killed, IL-4, IL-5, and interferon-γ levels were quantified in the lung tissue, which were examined histologically by light and electron microscopy.
There were significant improvements in all histopathological parameters in the group treated with suplatast tosilate compared with the vehicle control group. Similar improvements were observed when the group receiving prophylaxis and treatment with suplatast tosilate was compared with the vehicle control as well. There were no significant differences between the group receiving only prophylaxis with suplatast tosilate and the vehicle control group. Cytokine levels were significantly higher in the vehicle control group when compared with the control group. Although all of the groups had lower cytokine levels than those of the vehicle control group, the differences were not statistically significant.
Treatment with suplatast tosilate was effective in improving all histopathological parameters in a mouse model of chronic asthma. It was observed that the use of prophylactic suplatast tosilate was ineffective and had no additional effects when administered together with treatment.
苏普拉司他托西酸盐是一种抑制 TH2 型细胞因子的药物。我们旨在研究苏普拉司他托西酸盐治疗和预防对慢性哮喘小鼠模型肺组织病理学和细胞因子水平的影响。
42 只 BALB/c 小鼠分为 6 组：I 组（对照组）、II 组（载体对照组）、III 组（地塞米松组）、IV 组（苏普拉司他托西酸盐预防组）、V 组（苏普拉司他托西酸盐治疗组）和 VI 组（苏普拉司他托西酸盐预防和治疗组）。除对照组和载体对照组外，所有组均用卵清蛋白致敏和攻击。除仅接受苏普拉司他托西酸盐预防治疗的研究组外，其余研究组的小鼠均接受研究药物治疗。处死小鼠后，检测肺组织中 IL-4、IL-5 和干扰素-γ 水平，并通过光镜和电镜观察组织学变化。
与载体对照组相比，苏普拉司他托西酸盐治疗组的所有组织病理学参数均有显著改善。与载体对照组相比，接受预防和治疗的苏普拉司他托西酸盐组也观察到类似的改善。仅接受苏普拉司他托西酸盐预防治疗的组与载体对照组之间无显著差异。与对照组相比，载体对照组的细胞因子水平显著升高。尽管所有组的细胞因子水平均低于载体对照组，但差异无统计学意义。
在慢性哮喘小鼠模型中，苏普拉司他托西酸盐治疗可有效改善所有组织病理学参数。观察到预防性使用苏普拉司他托西酸盐无效，与治疗一起使用也没有额外效果。
